peritoneal cavity, to culture the test mixture; and (3) the dominant lethal test, in which male mice or rats are treated with the drug and mated with a series of (usually untreated) females. The latter are killed in mid-pregnancy and counts of implantation and resorption sites, and of viable feetuses are made.
The predictive value of such tests has yet to be established, as have their advantages over the current well-conducted reproductive and teratological tests used in evaluating safety. REFERENCES Fitzhugh 0 G (1959) The Biological Division of the Weilcome Research Laboratories is the largest single manufacturer of vaccines, antisera and diagnostic reagents in this country. It is also concerned with research and development aimed at understanding more about the basic mechanisms of immunity and devising more effective means of producing clinical immunity or tolerance, so that existing products may be improved and new ones prepared.
During the year 1969-70 we used very large numbers ofanimals which cost us about £200,000; in addition there is the cost of their maintenance, housing and feeding whilst in our laboratories. The economic incentive to reduce the number of animals used is therefore strong, yet the numbers used increase inexorably.
The total numbers that we use, including animals that are used to provide meat for media production or normal serum, amount to over 300,000. In addition, we use 750,000 fertile eggs. Usage has been divided into several classes and it is found that the large majority of the animals used are employed in tests to establish potency and safety of products.
The quality of animals is of vital importance, especially for the provision of substrate for virus vaccine production or testing. The solutionpartial only at presentto this problem is the substitution of tissue cultures for animals. Cells can be established in continuous culture and stored at low temperatures whilst aliquots are tested exhaustively for freedom from microbial contamination and general safety. The use of such preserved cells has been in large scale use for veterinary virus vaccines like those for foot and mouth and Newcastle diseases. Last year a living attenuated rubella vaccine grown in a human diploid cell strain W138 was licensed in this country. This has reduced the dependence on variable animal hosts and introduced to the substrate for virus vaccine the same seed concept that has been found necessary to control the quality of attenuated microbes. In the early days of vaccinia or BCG vaccines serial passage of the strain occurred, with resulting variations in quality. It gradually became possible, as good techniques of preservation were developed, to produce stable master seeds of vaccine shown to be effective and safe in man and use these for vaccine production. Now a similar seed system can be employed for the cell substrate used for the production of virus vaccines.
Animals have to be used for many purposes, particularly for safety and potency testing. Any reduction in their numbers for these purposes has to come from using larger batches of vaccine, or the improvement of their quality so that more uniform and regular results are obtained. Similar improvements in quality are being sought in other applications so that, for example, higher antibody levels are achieved from animals used for antibody production. By comparison, the usage of animals for research programmes is relatively small, but none the less vital to continued progress in the prevention of disease of man and animals. Medicines mean medicinal products as defined in Section 130 of the Medicines Act, 1968. In the context of this paper, only a limited area of such a wide group will be referred to. Almost any animals can be and have been involved but the most commonly used are mice, rats, guinea-pigs and rabbits. Monkeys, cattle and horses are used in fewer numbers. Domestic pets do not feature prominently.
The animals are used in the development of new medicinal products, as a source of raw material for medicinal products, and as a means of testing of intermediate or final products. The law has long played a prominent role in connexion with the testing of batches of certain productsthose governed under the Therapeutic Substances Acts, 1925 and 1956. It is expected that this role will be continued and expanded under the Medicines Act, 1968. The law has also played some part in connexion with the use of animals as sources of raw material, again in the context of the Therapeutic Substances Act, and this part will continue under the Medicines Act. The law as defined in this paper plays little or no part in connexion with the use of animals in the development of new medicinal products. The role of the biochemist in medical research is to describe a pathological situation in chemical terms. Analysis of biological fluids and tissues from a patient may be helpful but the use of a suitable animal model is likely to be more informative. It has the advantage that one can study, in controlled experiments, the nature of the biochemical abnormality as well as the effect of different treatments. Jaundice in the newborn is caused mainly by an inability to form bilirubin glucuronide, due to a deficiency of the enzyme bilirubin glucuronyl transferase (Lathe & Walker 1958) . In hemolytic disease and premature infants this may result in the development of an encephalopathy, known as kernicterus, which is associated with the accumulation of bilirubin in certain areas of the brain (Claireaux 1950) . This situation is also encountered in a mutant strain of rat which was first described by Gunn in 1938. These rats become icteric 6 hours after birth and then remain jaundiced for life. Malloy & Lowenstein (1940) showed that the jaundice was caused by an inability to produce 'direct reacting' (conjugated) bilirubin. Seventeen years later it was established that these animals had an absolute deficiency of the enzyme bilirubin glucuronyl transferase (Lathe & Walker 1958) .
Like the newborn infant the Gunn rat tends to develop neurological abnormalities with kernicterus during the neonatal period; the type of brain damage found is almost identical with that seen in the human infant. The Gunn rat was, therefore, the ideal animal in which to investigate the reason for the tragedy of the prophylactic antibiotic trial in a premature nursery in which it was found that the incidence of kernicterus in the infants receiving sulfisoxazole was 19 times that in the group receiving penicillin and oxytetracycline, in spite of the fact that their mean serum bilirubin level was only 8-0 mg/100 ml compared with 16-4 mg/100 ml in the latter group (Silverman et al. 1956 ). Johnson et al. (1959 designed experiments which showed that these findings were due to the sulfa drug competing with bilirubin for binding sites on the plasma albumin molecule so that the amount of 'unbound bilirubin' available for transfer across the blood-brain barrier into the brain was increased. These investigators demonstrated that salicylates had a similar effect on the Gunn rat so that it is now evident that special consideration must be given to the choice of drugs for the newborn.
The Gunn rat has also been used to examine the mechanism of action of different treatments for jaundice as well as to test for possible sideeffects. Exposure to blue light is known to increase the speed with which jaundice disappears in the premature infant (Cremer et al. 1958) and is now an accepted form of treatment for many pediatricians. There are, however, some critics who fear that the treatment may have an undetected toxic effect. In order to investigate this possibility Ostrow (1971) has studied the effect of blue light on Gunn rats with bile fistula after labelling their bilirubin pool with ("IC) bilirubin. He observed that there was a marked increase in the radioactivity excreted in the bile due mainly to increased metabolism of (14C) bilirubin. In addition, there was the unexpected finding of a marked increase in the rate of excretion of unconjugated bilirubin in the bile. This suggests that the treatment may have affected the permeability of the liver cell. Further investigations are therefore necessary before one can conclude that, on a long-term basis, blue light causes no harmful effects.
Information regarding the metabolism of bilirubin in the hyperbilirubinemic patient with a congenital deficiency of the conjugating enzyme
